文献速递糖尿病

情绪困扰可预测2型糖尿病治疗依从性降低:来自GRADE研究的结果

Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
PubMed 文献 · Diabetes Care · 2024-01-01

本研究基于GRADE随机对照试验中的情绪困扰子研究,对1739名近期起病的2型糖尿病成人每半年一次问卷随访至3年,考察基线抑郁症状和糖尿病困扰与36个月用药依从性的纵向关联。结果显示基线抑郁症状和糖尿病困扰越高,36个月依从性越低,且情绪困扰可预测随后6个月依从性降低而非反之;对糖尿病药物的担忧介导了最大比例的关联。

要点

  • 基线抑郁症状和糖尿病困扰越高,36个月用药依从性越低(P < 0.001)。
  • 某一访视时抑郁症状和糖尿病困扰越高,预测随后6个月访视依从性越低(P < 0.0001),反向不成立。
  • 对糖尿病药物的担忧介导了情绪困扰与依从性纵向关联的最大比例(11.9%-15.5%)。

核心结论

  • 在2型糖尿病成人中,抑郁症状和糖尿病困扰均可预测降糖药物依从性随时间降低。
  • 处理情绪困扰及对服用这些治疗预期不良影响的担忧,可能对支持糖尿病治疗依从性很重要。

研究设计与样本

  • GRADE为大型随机对照试验,比较在二甲双胍基础上加用四种降糖药物的成人近期起病2型糖尿病患者。
  • 情绪困扰子研究通过每半年一次自填问卷评估1739名GRADE参与者的用药依从性、抑郁症状和糖尿病困扰,随访至3年。
  • 分析基线抑郁症状和糖尿病困扰对36个月用药依从性的预测,并检验访视间双向关系。
  • 评估治疗满意度、药物信念、糖尿病自我管理效能和感知糖尿病控制作为纵向关联的中介因素。

主要发现

  • 基线时参与者平均±SD年龄58.0 ± 10.2岁,糖尿病病程4.2 ± 2.8年,HbA1c 7.5% ± 0.5%,用药依从性89.9% ± 11.1%;56%为白人,17%为西班牙裔/拉丁裔,18%为黑人,66%为男性。
  • 基线抑郁症状和糖尿病困扰越高,独立关联36个月依从性越低(P < 0.001)。
  • 某一访视时抑郁症状和糖尿病困扰越高,预测随后6个月访视依从性越低(P < 0.0001),但反向不成立。
  • 治疗分组未调节上述关系。
  • 患者报告的對糖尿病药物的担忧介导了情绪困扰与依从性纵向关联的最大比例(11.9%-15.5%)。

临床怎么用

  • 作者认为,处理情绪困扰及对服用这些治疗预期不良影响的担忧,可能对支持糖尿病治疗依从性很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined longitudinal associations between emotional distress (specifically, depressive symptoms and diabetes distress) and medication adherence in Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), a large randomized controlled trial comparing four glucose-lowering medications added to metformin in adults with relatively recent-onset type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: The Emotional Distress Substudy assessed medication adherence, depressive symptoms, and diabetes distress in 1,739 GRADE participants via self-completed questionnaires administered biannually up to 3 years. We examined baseline depressive symptoms and diabetes distress as predictors of medication adherence over 36 months. Bidirectional visit-to-visit relationships were also examined. Treatment satisfaction, beliefs about medication, diabetes care self-efficacy, and perceived control over diabetes were evaluated as mediators of longitudinal associations. RESULTS: At baseline, mean ± SD age of participants (56% of whom were White, 17% Hispanic/Latino, 18% Black, and 66% male) was 58.0 ± 10.2 years, diabetes duration 4.2 ± 2.8 years, HbA1c 7.5% ± 0.5%, and medication adherence 89.9% ± 11.1%. Higher baseline depressive symptoms and diabetes distress were independently associated with lower adherence over 36 months (P < 0.001). Higher depressive symptoms and diabetes distress at one visit predicted lower adherence at the subsequent 6-month visit (P < 0.0001) but not vice versa. Treatment assignment did not moderate relationships. Patient-reported concerns about diabetes medications mediated the largest percentage (11.9%-15.5%) of the longitudinal link between emotional distress and adherence. CONCLUSIONS: Depressive symptoms and diabetes distress both predict lower adherence to glucose-lowering medications over time among adults with T2DM. Addressing emotional distress and concerns about anticipated negative effects of taking these treatments may be important to support diabetes treatment adherence.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hoogendoorn CJ, Krause-Steinrauf H, Uschner D, et al. Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. PMID: 38227900. doi:10.2337/dc23-1401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。